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Abstract
Background: A noninferiority trial was conducted to evaluate the efficacy of a single evening dose of fixed-
combination latanoprost 50 μg/mL and timolol 0.5 mg/mL (Xalacom®; LTFC), in Chinese patients with primary
open-angle glaucoma (POAG) or ocular hypertension (OH) who were insufficiently controlled on b-blocker
monotherapy or b-blocker-based dual therapy.
Methods: This 8-week, randomized, open-label, parallel-group, noninferiority study compared once-daily evening
dosing of LTFC with the unfixed combination of latanoprost, one drop in the evening, and timolol, one drop in
the morning (LTuFC). The primary efficacy endpoint was the mean change from baseline to week 8 in diurnal
intraocular pressure (IOP; mean of 8 AM, 10 AM, 2 PM, 4 PM IOPs). LTFC was considered noninferior to LTuFC if the
upper limit of the 95% confidence interval (CI) of the difference was < 1.5 mmHg (analysis of covariance).
Results: Baseline characteristics were similar for LTFC (N = 125; POAG, 70%; mean IOP, 25.8 mmHg) and LTuFC (N
= 125; POAG, 69%; mean IOP, 26.0 mmHg). Mean diurnal IOP changes from baseline to week 8 were -8.6 mmHg
with LTFC and -8.9 mmHg with LTuFC (between-treatment difference: 0.3 mmHg; 95%-CI, -0.3 to 1.0). Both
treatments were well tolerated.
Conclusions: A single evening dose of LTFC was at least as effective as the unfixed combination of latanoprost in
the PM and timolol in the AM in reducing IOP in Chinese subjects with POAG or OH whose IOP was insufficiently
reduced with b-blocker monotherapy or b-blocker-based dual therapy. LTFC is an effective and well tolerated
once-daily treatment for POAG and OH.
Trial registration: Clinicaltrials.gov registration: NCT00219596
Background
In China, 158 million people are over the age of 60, with
the number projected to increase to approximately 250
million by the year 2020 [1]. As the median age rapidly
rises, age-related diseases of the eye are emerging as a
major public health issue. Primary open-angle glaucoma
(POAG) in Chinese individuals over the age of 40 years
has an estimated prevalence of approximately 1.5% to
2% [2]. Reliable data concerning the prevalence in China
of ocular hypertension (OH), characterized by intraocu-
lar pressure (IOP) > 21 mmHg without ocular nerve
damage and visual field loss, are not available.
Monotherapy with b-adrenergic antagonists such as
timolol 0.5%, which lowers IOP levels by reducing aqu-
eous humor outflow [3-5], continues to be among the
most widely used approaches to treating POAG and OH
in China. Although timolol generally is well tolerated, a
significant proportion of timolol-treated patients does
not achieve targeted IOP levels [6], and approximately
one-third require a change in or addition to initial
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timolol monotherapy after 1 year, a proportion that
increases to one-half after 2 years [7].
Latanoprost 0.005%, a selective prostaglandin F2a
receptor agonist that has a mechanism of action com-
plementary to that of timolol (i.e., acts mainly by
increasing outflow) [8], has been shown to be an effec-
tive treatment for POAG and OH as monotherapy
[9-12]. Results of a cross-national meta-analysis sug-
gested that there is an efficacy advantage for latanoprost
compared to timolol in Chinese patients with POAG
that is independent of other clinical and demographic
variables [13].
Patients who do not achieve target IOP levels with a
single ocular hypotensive agent often are prescribed
concomitant therapy with a medication that has a dif-
ferent mechanism of action, an approach supported by
the American Academy of Ophthalmology [14] and the
European Glaucoma Society [15]. In patients with
POAG or OH whose IOP is not sufficiently controlled
on timolol monotherapy, concomitant treatment with
latanoprost has demonstrated additive IOP-reducing
efficacy [10,16-18]. Moreover, in a double-masked
comparison, evening dosing of fixed-combination lata-
noprost/timolol (Xalacom®; LTFC) was found to be at
least as effective as latanoprost instilled once daily in
the evening and timolol administered in both the
morning and evening [19].
The purpose of the current study in Chinese patients
was to evaluate the efficacy and tolerability of a single
evening dose of LTFC versus the unfixed combination
of latanoprost administered once daily in the evening
and timolol dosed once daily in the morning (LTuFC).
Methods
Study design
This was an 8-week, randomized, open-label, parallel-
group study conducted at 8 sites in China between June
30, 2005, and September 13, 2006 (NCT00219596). The
study was conducted in accordance with the tenets of
the Declaration of Helsinki and with all Chinese regula-
tory requirements and was approved by the Ethics Com-
mittee of Peking Union Medical College Hospital,
Beijing, China. Written informed consent was obtained
from study participants prior to study entry.
Subjects
Males or females were eligible if they were 18 years of
age or older, were diagnosed with POAG or OH and
had been treated for at least the 4 weeks immediately
prior to screening with b-blocker monotherapy or with
a b-blocker-based dual therapy. At the screening visit,
the IOP was required to be ≥17 and ≤35 mmHg in at
least 1 eye at both the 8 AM and 10 AM measurement
time points. At the baseline visit after washout
(described below), IOP measured at 10 AM was
required to be ≥21 and ≤35 mmHg and ≥25% higher
than the IOP level at screening in at least 1 eye (same
eye at both time points) for b-blocker monotherapy
users, or ≥21 and ≤35 mmHg and ≥30% higher than the
IOP at screening in at least 1 eye (same eye at both
time points) for those treated with b-blocker-based dual
therapy.
Potential subjects were excluded if they met any of the
following criteria: (1) closed/barely open anterior cham-
ber angle or a history of acute angle-closure glaucoma;
(2) ocular surgery in one or both eyes within 3 months
prior to the screening visit; (3) any condition in one or
both eyes that could prevent reliable applanation tono-
metry; (4) ocular inflammation/infection occurring
within 1 month prior to the screening visit; (5) use, or
planned use, of any topical or systemic medication
known to affect IOP; (6) known hypersensitivity to ben-
zalkonium chloride or to any component of the study
drug solutions; (7) any ocular or medical condition in
which treatment with b-blocking agents is contraindi-
cated; and (8) any acute or uncontrolled medical or psy-
chiatric illness. Pregnant or lactating women or women
of childbearing potential not using an acceptable
method of contraception also were excluded.
Treatments and Assessments
After initial screening, subjects completed a washout
period that varied in length depending on the current
drug as follows: 4 weeks for b-adrenergic antagonists
and prostaglandin analogs (including latanoprost, bima-
toprost, travoprost, and unoprostone); 2 weeks for adre-
nergic agonists; and 5 days for cholinergic agonists and
carbonic anhydrase inhibitors.
After the washout period, all eligible subjects were
assigned a randomization number by the site coordina-
tor. Subjects were randomized in a 1:1 ratio according
to a computer-generated pseudorandomization number
generator using random permuted blocks with a fixed
block size to the LTFC or LTuFC group. Each site was
provided with sealed envelopes marked with sequential
randomization numbers containing the name of the
treatment to which the subject was randomized. Envel-
opes were returned to the sponsor at study completion.
Randomized subjects received either one drop of LTFC
at approximately 8 PM or the LTuFC consisting of one
drop of latanoprost 0.005% at approximately 8 PM and
one drop of timolol 0.5% at approximately 8 AM. At the
baseline visit, subjects received study medication suffi-
cient for 4 weeks; at the week 4 visit, medication suffi-
cient for the remaining 4 weeks of the study was
dispensed. Postbaseline study visits occurred at weeks 1,
2, 4, 6, and 8. Study medication was discontinued at
week 8 whereupon subjects continued therapy with
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available medication. Subjects had a final follow-up visit
at week 10.
IOP was measured at 8 AM and 10 AM at screening;
at 8 AM, 10 AM, 2 PM, and 4 PM at baseline and week
8 (or early discontinuation); and at 8 AM only at weeks
1, 2, 4, and 6. At each measurement time point, two
assessments were performed in each eye, alternating
between eyes, and the IOP at a given time point was
defined as the average of the two measures. For each
subject, IOP assessments were made by the same exami-
ner using the same calibrated Goldmann applanation
tonometer at each visit. Additional evaluations per-
formed at each visit included assessment of systemic
and ocular adverse events; recording of vital signs; visual
acuity measurement; and lid, slit lamp, and ophthalmo-
scopy examinations of eye structures. Visual field exami-
nations were performed at screening and week 8.
Endpoints and analyses
The primary efficacy endpoint was change from baseline
in mean diurnal IOP at week 8. If only one eye was eligi-
ble, the diurnal IOP for each measurement day was the
mean of IOP measurements at 8 AM, 10 AM, 2 PM, and
4 PM of the study eye. If both eyes were eligible, the diur-
nal IOP for each measurement day was calculated as the
mean of diurnal IOP levels across study eyes.
The study was designed to evaluate whether LTFC
was noninferior to LTuFC, i.e., was either more or simi-
larly effective. Between-group differences were evaluated
using an analysis of covariance (ANCOVA) model with
baseline diurnal IOP as a covariate and treatment and
center as factors. The treatment difference (ΔLTFC -
ΔLTuFC) and the corresponding 95% confidence inter-
val (CI) for the difference were calculated. LTFC was
considered noninferior to LTuFC if the upper limit of
the 2-sided 95% CI of the difference was < 1.5 mmHg.
A sample of 100 subjects per treatment group was esti-
mated to provide at least 85% power using a 1-sided
test with a 2.5% significance level.
For secondary efficacy endpoints, the statistical signifi-
cance of between-group differences in mean 8 AM IOP
at weeks 1, 2, 4, 6, and 8 and mean change in IOP from
baseline to week 8 at each measurement time point
were analyzed using the ANCOVA method described
with regard to the primary endpoint. Between-group dif-
ferences in proportions of subjects reaching prespecified
diurnal IOP levels of ≤21, ≤18, ≤16, and ≤14 mmHg at
week 8 were evaluated using the Cochran-Mantel-
Haenszel test.
Intent-to-treat (ITT) efficacy analyses included all sub-
jects who received study medication, had an IOP mea-
surement at baseline, and had at least one valid
postbaseline IOP measurement. Missing efficacy data
were imputed using the last observation carried forward
(LOCF) method; baseline values were not carried
forward.
Results
In all, 279 subjects were screened, and 250 completed
the 4-week washout period, continued to meet eligibility
criteria, and were randomized to study treatment (Figure
1). In the LTFC group, both the safety and ITT popula-
tions included the 125 subjects who received treatment.
In the LTuFC group, one subject did not receive study
medication and one did not have required IOP measure-
ments; the safety and ITT populations for this group
included 124 and 123 subjects, respectively. In both
treatment groups, 120 of 125 screened subjects (96%)
completed the study.
Subjects’ demographic and baseline clinical characteris-
tics are summarized in Table 1. With the exception of a
somewhat greater proportion of females in the LTFC
group (53% vs. 40%, respectively), treatment groups were
similar with regard to age, diagnosis, mean baseline IOP,
and prior ocular hypotensive medication. Four subjects
(3.2%) in each treatment group had a history of diabetes
mellitus; 16 (12.8%) subjects in the LTFC and 12 (9.6%)
in the LTuFC group had a history of hypertension.
Efficacy
At baseline, mean diurnal IOP levels were approximately
26 mmHg in both treatment groups (Table 2). Mean
IOP reductions of > 8 mmHg from baseline to week 8
were observed in both groups (P < 0.001 for each
group). The least square mean reduction in diurnal IOP
from baseline to week 8 was 8.6 mmHg in LTFC-treated
subjects and 8.9 mmHg among those treated with
LTuFC. The between-group difference was 0.3 mmHg
(95% CI: -0.3, 1.0); the upper bound of the 95% CI was
< 1.5 mmHg, indicating noninferiority of LTFC.
No statistically significant between-group differences
were noted in proportions of subjects reaching prespeci-
fied percentage mean diurnal IOP levels at week 8 (Fig-
ure 2).
The IOP-reducing effect of both the fixed and unfixed
combinations was evident at week 1 and was sustained
through week 8. Mean 8 AM IOP levels were reduced
significantly (P < 0.001) from baseline at weeks 1, 2, 4,
6, and 8 in both treatment groups, and no between-
groups difference in reduction was statistically signifi-
cant (Figure 3). At week 8, least square mean IOP
reductions from baseline were similar across treatments
at all measurement time points (Figure 4).
Adverse events
The incidence of all-causality treatment-emergent
adverse events was low in both treatment groups, with
11.2% of those receiving LTFC and 6.5% of subjects
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treated with LTuFC reporting at least one such event
(Table 3). No event in either group was considered by
an investigator to be severe or serious. Conjunctival
hyperemia was the only adverse event to occur in > 3%
of subjects in either group and was reported in 7.2% of
those treated with LTFC and 4.8% of subjects in the
LTFC (n = 125)
Screened (N = 279)
Safety population (n = 125)
Assigned to study treatment* (N = 125)
       As randomized                (n = 124)
       Receiving treatment different
       from randomization           (n = 1)
Randomized (N = 250)
LTuFC (n = 125)
Assigned to study treatment* (N = 125)
       As randomized                (n = 124)
       Receiving treatment different
       from randomization           (n = 1)
Safety population (n = 124)
ITT population (n = 125) ITT population (n = 123)
Figure 1 Analysis population classification. LTFC = latanoprost/timolol fixed combination; ITT = intent-to-treat population; LTuFC =
latanoprost/timolol unfixed combination.





Female, n (%) 66 (52.8) 50 (40.3)




Primary open-angle glaucoma, n (%) 87 (69.6) 85 (68.5)
Duration since diagnosis, years, mean
(range)
4.2 (0.1-30) 3.1 (0.1-33)
Ocular hypertension, n (%) 38 (30.4) 39 (31.5)
Duration since diagnosis, years, mean
(range)
2.7 (0.2-25) 2.3 (0.2-10)
Baseline IOP, mmHg, mean ± SD† 25.8 ± 3.2 26.0 ± 3.5
Prior medications in ≥10% of subjects, n (%)
Brinzolamide 101 (80.8) 93 (75.0)
Carteolol hydrochloride 49 (39.2) 42 (33.9)
Timolol maleate 28 (22.4) 33 (26.6)
Timolol 22 (17.6) 24 (19.4)
Carteolol 15 (12.0) 13 (10.5)
*Safety population.
†Includes subjects with data at both baseline and week 8; N = 123 for the
LTuFC group.
LTFC = latanoprost/timolol fixed combination; IOP = intraocular pressure; SD =
standard deviation; LTuFC = latanoprost/timolol unfixed combination.






Baseline, mean ± SD 25.8 ± 3.2 26.0 ± 3.5
Week 8, mean ± SD 17.5 ± 2.9 17.2 ± 3.0
Change from baseline to week 8, mean ±
SD
-8.3 ± 3.2 -8.8 ± 3.8




LS mean change -8.6 -8.9
Difference in LS means (95% CI) 0.3 (-0.3 to 1.0)
*Intent-to-treat population.
CI = confidence interval; LTFC = latanoprost/timolol fixed combination; IOP =
intraocular pressure; LS = least square; SD = standard deviation; LTuFC =
latanoprost/timolol unfixed combination.
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LTuFC group. Two subjects in each group discontinued
due to an adverse event (LTFC: blurred vision of moder-
ate severity, right bundle branch block; LTuFC: mild
chest pain, viral conjunctivitis); one discontinuation in
each group was considered to be treatment related
(LTFC: blurred vision; LTuFC: mild chest pain). No
clinically significant, treatment-emergent abnormalities
in vital signs were noted in either treatment group dur-
ing the study, and there were no clinically important
between-group differences in ocular safety assessments
or visual field examination findings.
Discussion
In patients needing two drugs to achieve therapeutic
goals, fixed-combination agents such as LTFC may have
advantages over the multiple ocular hypotensives
instilled at different times of day. In particular, compli-
ance may be improved with the convenience of once-
daily dosing, an important consideration since medica-
tion compliance among patients with POAG and OH
has been shown to be reduced with more complex med-
ication regimens [20-24], and poor adherence has been
associated with vision decreases in glaucoma patients
[25,26]. In addition, once-daily dosing may result in cost
savings as well as less exposure to preservatives such as



























Figure 2 Proportion of subjects achieving prespecified IOP
levels at week 8*. *Intent-to-treat population. No significant
between-group differences based on the Cochran-Mantel-Haenszel
test. LTFC = latanoprost/timolol fixed combination; IOP = intraocular








LTFC, N = 125
LTuFC, N = 123




















Figure 3 Mean 8 AM IOP across 8 weeks of treatment*. *Intent-
to-treat population. P < 0.001 for baseline to postbaseline treatment
difference based on analysis of covariance with treatment and
center as factors and baseline 8 AM IOP as a covariate. LTFC =
latanoprost/timolol fixed combination; IOP = intraocular pressure;
LTuFC = latanoprost/timolol unfixed combination.
LTFC, N = 125


























Figure 4 Mean change in IOP from baseline to week 8 at each
measurement time point*. *Intent-to-treat population. P > 0.17 for
each between-treatment difference based on analysis of covariance
with treatment and center as factors and baseline diurnal IOP as a
covariate. LTFC = latanoprost/timolol fixed combination; IOP =
intraocular pressure; LS = least square; LTuFC = latanoprost/timolol
unfixed combination.






Subjects with ≥1 adverse event 14 (11.2) 8 (6.5)
Subjects with ≥1 severe adverse
Event
0 0
Subjects with ≥1 serious adverse
Event
0 0
Conjunctival hyperemia 9 (7.2) 6 (4.8)
Visual field defect (mild) 3 (2.4) 0
Eye irritation 1 (0.8) 0
Eyelid cyst 1 (0.8) 0
Eyelid disorder 1 (0.8) 0
Vision blurred 1 (0.8) 0
Right bundle branch block 1 (0.8) 0
Chest pain 0 1 (0.8)
Viral conjunctivitis 0 1 (0.8)
*Safety population.
LTFC = latanoprost/timolol fixed combination; LTuFC = latanoprost/timolol
unfixed combination.
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This 8-week, randomized, open-label study in Chinese
patients with POAG or OH whose IOP was insuffi-
ciently controlled on a b-blocker administered either as
monotherapy or as part of dual therapy demonstrated
that both once-daily LTFC administered in the evening
and the unfixed combination of latanoprost dosed in the
evening and timolol administered in the morning signifi-
cantly lowered IOP levels from baseline. In both groups,
mean IOP levels were reduced from 26 mmHg at base-
line to approximately 17 mmHg at week 8. For the pri-
mary endpoint, the between-group difference in least
square mean diurnal IOP reductions from baseline to
week 8 was 0.3 mmHg and the upper limit of the 95%
CI was < 1.5 mmHg supporting the noninferiority of
LTFC. These findings and the conclusion of noninferior-
ity are similar to results of a randomized, double-
masked trial [19] in which mean diurnal IOP reductions
from baseline to week 12 were 8.7 and 9.0 mmHg with
LTFC and LTuFC (timolol dosed twice daily), respec-
tively, and the between-treatment difference was 0.3
mmHg (95% CI: -0.1, 0.7 mmHg; P = 0.15). At last mea-
surement (8 weeks herein and 12 weeks in Diestelhorst
and Larsson [19]), approximately 90% of subjects in
both treatment groups achieved mean diurnal IOP levels
≤21 mmHg, and > 30% had mean diurnal IOPs ≤16
mmHg.
A recent systematic review and meta-analysis of 29
randomized clinical trials of the IOP-lowering effect of
prostaglandins combined with topical b-blockers [29]
found equivalent IOP reductions with morning or eve-
ning instillation of fixed combinations of timolol and a
prostaglandin analog. However, only 24-hour studies are
appropriate when addressing morning versus evening
administration, and several studies have shown that the
relative efficacy of LTFC and latanoprost reflects instilla-
tion time. For example, a study by Alm et al [9] as well
as several by Konstas et al [30-32] demonstrated that
evening dosing of latanoprost and LTFC provided lower
daytime IOP levels than morning dosing. A study by
Konstas and associates [32] showed that LTFC com-
pared to latanoprost monotherapy, both dosed in the
evening, provided a wider margin (2.5 mmHg more than
latanoprost) over 24 hours than the morning dosing
used in a regulatory trial [33]. In another crossover
study [34], 24-hour IOP fluctuation was significantly
lower with LTFC dosed in the evening compared with
timolol alone (3.2 mmHg vs 4.4 mmHg, respectively; P
= 0.003). Finally, a direct 24-hour IOP comparison
between morning and evening administration of LTFC
in POAG patients found that evening dosing provided
more effective IOP control [35].
In addition to the issue of administration time, no
study of LTFC has included evenly distributed trough
and peak measurements [29]. Moreover, although
timolol administered once daily has been shown to
achieve maximum IOP reduction [36], the impact of cir-
cadian rhythm remains to be clarified. Peak IOP values
in the morning and nadir values in the evening have
been reported for both healthy elderly volunteers [37]
and for untreated individuals with glaucoma [38]. In the
current study, IOP assessments were limited to the per-
iod between 8 AM and 4 PM, which coincided with the
first 8 hours after the morning administration of timolol
in the unfixed combination.
The meta-analysis [29] found that greater IOP lower-
ing occurred with concomitant timolol twice daily and
latanoprost once daily than with LTFC, a difference that
may reflect the omission of a timolol dose with the
fixed combination. Herein, timolol was administered
once daily in the morning in the LTuFC arm rather
than twice daily as is more typical with unfixed regi-
mens. Instillation of one dose of timolol in the morning
in both treatment arms may explain, in part, the rela-
tively small between-group difference in mean IOP
reduction.
Consistent with the results of previous studies
[19,27,39-41], both the fixed and unfixed combinations
of latanoprost/timolol were well tolerated. Rates of treat-
ment-emergent adverse events were somewhat lower in
the present study than reported by Diestelhorst and
Larsson [19] possibly reflecting the difference in follow-
up (8 weeks vs 12 weeks, respectively). In the present
study, only one adverse event (conjunctival hyperemia)
occurred in > 3% of subjects in each treatment group,
and only two subjects in each group discontinued due
to treatment-related adverse events. There were no
clinically important between-group differences in treat-
ment-emergent changes in ocular safety assessments. It
is important to note, however, that the duration of the
present study was too short to identify possible long-
term adverse treatment effects.
This is the first study to compare the efficacy and tol-
erability of LTFC with that of LTuFC in a Chinese
population, a population that represents an increasingly
large proportion of individuals with POAG or OH
worldwide. The study is limited by its open-label design.
However, the randomization of subjects and the assess-
ment of outcomes at multiple visits and the fact that
our results closely parallel those of a prior double-
masked study [19] suggest that the impact of the open-
label design may have been minimal. The research also
was limited by its short time frame since follow-up peri-
ods of several years would be needed to assess the pro-
gression of glaucomatous damage. Although Watson et
al [12] found that POAG patients treated with latano-
prost monotherapy experienced a significantly greater
mean IOP reduction than similarly treated OH patients
(9.4 mmHg vs 7.1 mmHg, respectively), such an analysis
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was not prespecified in the present study; future
research might profitably compare differences between
these diagnosis groups in Chinese patients.
Conclusion
Single nighttime dosing with LTFC is well tolerated and
at least as effective as concomitant administration of
latanoprost and timolol each administered once daily.
The benefits of combination treatment argue for its con-
sideration by clinicians when two drugs are needed to
meet therapeutic goals.
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